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Abstract
Background: The presence of IgG and IgM against Tat, an HIV protein important for viral replication and immune
dysfunction, is associated with slow disease progression in clade B HIV-infected individuals. However, although Tat
activities strictly depend on the viral clade, our knowledge about the importance of anti-Tat antibodies in non-clade
B HIV infection is poor. The objective of this study was to investigate the association of different anti-Tat antibody
isotypes with disease progression in non-clade B HIV-infected subjects and to study the relationship between
anti-Tat humoral responses and immunological abnormalities.
Methods: Anti-clade B and -clade C Tat IgG, IgM and IgA titers were assessed in serum samples from 96 cART-naïve
subjects with chronic HIV infection from Mbeya, Tanzania, and associated with CD4+ T cell count, plasma viremia
and CD4+ and CD8+ T cell phenotypes.
Results: Anti-Tat IgM were preferentially detected in chronic HIV-infected subjects with low T cell activation
(p-value = 0.03) and correlated with higher CD4+ T cell counts and lower viral loads irrespective of the duration of
infection (p-value = 0.019 and p-value = 0.037 respectively). Conversely, anti-Tat IgA were preferentially detected in
individuals with low CD4+ T cell counts and high viral load (p-value = 0.02 and p-value < 0.001 respectively). The
simultaneous presence of anti-Tat IgG and IgM protected from fast CD4+ T cell decline (p-value < 0.01) and
accumulation of CD38+HLADR+CD8+ T cells (p- value = 0.029).
Conclusions: Anti-Tat IgG alone are not protective in non-clade B infected subjects, unless concomitant with IgM,
suggesting a protective role of persistent anti-Tat IgM irrespective of the infecting clade.
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Background
The HIV Tat protein is fundamental for HIV infection,
replication and dissemination. Tat is a transcriptional
transactivator of the HIV genome [1] which favours the
generation of new activated CD4+ T cell targets for
infection [2–4] and interacts with Env enhancing viral
infectivity [5, 6]. Tat activity also induces the release of
pro-inflammatory cytokines and up-regulation of tran-
scription factors involved in T cell activation contributing
to hyperactivation and dysfunction of T cells [2, 3, 7–10].
Moreover, Tat interacts with various co-infecting oppor-
tunistic pathogens [11] and is directly implicated in the
pathogenesis of AIDS-related Kaposi’s sarcoma [12],
several vasculopathic conditions [13] and HIV-associated
dementia [14]. Interestingly, the effects of Tat differ de-
pending on the HIV clade [14–16].
Anti-Tat immunity might counteract the Tat-mediated
immune dysregulation and hence play a role in control-
ling HIV infection and co-morbidity. Previous studies
showed that anti-Tat IgM and IgG, although present in a
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small proportion of HIV-infected individuals, are more
frequently found in the asymptomatic stage of infection
[17, 18] and in non-progressors [19] and are associated
with maintenance of CD4+ T cell counts [20–22] and
low viral load [23, 24]. However, most of these studies
were conducted in clade B HIV-infected cohorts and
with clade B Tat, whereas the effect of naturally occur-
ring anti-Tat antibodies in non-clade B HIV infections
has been poorly investigated and the relationship be-
tween anti-Tat humoral responses and the development
of immunological abnormalities has not been reported.
In this study, a comprehensive analysis of different
anti-Tat antibody isotype levels was conducted to
investigate the association of anti-Tat IgG, IgA and IgM
with CD4+ T cell count, viral load and immunological




Human serum samples from 96 cART-naïve chronic-
ally HIV-infected adults (minimum duration of infec-
tion of >1 year) from the “Worm_HIV_Interaction_Study”
(WHIS) cohort, Mbeya Medical Research Center, Mbeya,
Tanzania, were included in the analyses. Characteristics of
study subjects are shown in Table 1. The WHIS cohort
study is described in detail elsewhere [25].
Absolute CD4+ T cell counts were determined from
anti-coagulated whole blood using a BD FACS Multitest
IMK kit (BD) according to manufacturer instructions.
HIV-1 plasma RNA concentrations were measured in
plasma samples of HIV positive subjects using either the
Cobas Amplicor HIV-1 Monitor Test version 1.5 or
Cobas Taqman 48 analyzer (Roche Diagnostics).
Enzyme-linked immunosorbent assay (ELISA)
Human anti-Tat IgG, IgM and IgA were measured in
sera by ELISA [17, 22, 26–29] using sera collected dur-
ing the baseline visit. Ninety-six-well immunoplates
(Nunc Max Sorp) coated with 100 ng/well of clade B or
clade C Tat (Diatheva, Additional file 1) resuspended in
0.05 M sodium carbonate buffer (pH 9.6–9.8), for 16 h
at 4 °C. Plates were washed five times with PBS (pH 7.0)
containing 0.05 % Tween-20 (Sigma) and then blocked
with PBS containing 0.05 % Tween 20 and 1 % BSA for
90 min at 37 °C (IgG) or 60 min at room temperature
(IgA) or with PBS containing 5 % milk for 60 min at 37 °C
(IgM). Plates were washed five times and 100 μl/well of
appropriate dilutions of each serum diluted in PBS con-
taining 0.05 % Tween 20 and 1 % BSA (“blocking buffer”
IgG and IgA) or PBS containing 5 % milk (“blocking
buffer” IgM) were dispensed in duplicate wells and then
incubated for 90 min at 37 °C. Plates were washed again
before the addition of 100 μl/well of HRP-conjugated
anti-human IgG (Sigma), diluted 1:1000, or HRP-
conjugated anti-human IgA (Sigma) diluted 1:3000, or
HRP-conjugated anti-human IgM (Sigma), diluted 1:1000,
in the appropriate blocking buffer and incubated at 37 °C
for 90 min (IgG) or for 60 min (IgA and IgM). In each
plate, two wells were incubated with blocking buffer plus
secondary antibodies (blank). After incubation, plates were
washed five times and incubated with blocking buffer for
15 min at 37 °C (step performed only for IgG and IgM).
Plates were washed five times and then incubated with
ABTS (Roche) for 50 min after which time absorbance
values were measured at 405 nm with an automatic plate
reader (SUNRISE TECAN). The cut-off value was esti-
mated as the mean absorbance of 3 negative control sera
plus 0.05. Negative control sera were randomly selected
from HIV-negative subjects enrolled in the WHIS cohort.
Blank and cut-off values were subtracted from the absorb-
ance value of each sample to obtain net absorbance values.
To determine the presence of anti-Tat antibodies, all sera
were first screened at a dilution of 1:100 for IgG and 1:25
for IgA and IgM. Then positive sera (net absorbance > 0)
were titrated using serial 2-fold dilutions. Serum samples
with anti-Tat IgG, IgA and IgM were considered positive
if antibody titers were ≥ 100, 25 and 25 respectively. Titers
were calculated by intercept function using the Excel pro-
gram (Microsoft).
ELISA assays were performed in a blinded way with
respect to immunological parameters and progression
markers.
Flow cytometry
The proportion of T cells expressing activation (HLA-DR
and CD38) and maturation (CD27 and CD45R0) markers
was determined in fresh, anti-coagulated whole blood as
previously described [25]. Briefly, fresh blood samples
were incubated for 30 min using the following
fluorochrome-labelled monoclonal antibodies (mABs):
CD3-Pacific Blue (BD), CD4 Per-CP Cy5.5 (eBioscience),
CD8 V500 or CD8 Amcyan, CD27 APC-H7, CD45RO
APC, HLA-DR FITC and CD38 PE (all from BD).
Table 1 Characteristics of the HIV positive individuals included
in the study (n = 96a)
Ageb 36.1 (28.8–42.3)
Female, n (%) 58 (60.4 %)
CD4+ T cell counts (cells/μl)b 398 (267–606)
Log10 pVL (copies/ml)
b 4.7 (4.0–5.3)
Duration of infection (n)c >1 year, < 3 years 20
>3 years 69
aNot all 96 subjects had data for each of the examined parameters (CD4,
n = 95; pVL, n = 89)
bValues shown are median and (Interquartile Range)
cDuration of infection could be confidentially estimated for 89 subjects out
of 96
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Acquisition was performed on a FACS CANTO II (BD).
Compensation was conducted with antibody capture
beads (BD) stained separately with the individual anti-
bodies used in the test samples. Flow cytometry data was
analysed using FlowJo (version 9.5.3; Tree Star Inc.).
Activation burden
The “activation burden” reported in this study refers to a
composite measure of T cell abnormalities defined by
the presence of 0, 1-2, 3 or more abnormalities of the T
cell phenotype. This approach was similar to that used
to define the “inflammatory burden” in HIV-infected in-
dividuals [30].
The correlation of CD4+ T cell counts and plasma viral
load (pVL) with the percentages of CD8+ and CD4+ T cell
subpopulations (single or double expression of HLA-DR/
CD38 or CD45RO/CD27) and the values of CD4:CD8 ratio
was assessed, and only those phenotypes that significantly
correlated (P-value Spearman’s correlation ≤0.05, not
shown) with disease progression (defined as the simultan-
eous decrease of CD4+ T cells number and increase of pVL)
were chosen as parameters to define the “activation bur-
den”. These parameters were the percentages of CD4+HLA-
DR+CD38+ and CD8+HLA-DR+CD38+ T cells (inverse
correlation with CD4+ T cell counts and direct correlation
with pVL), the percentages of CD4+CD45RO−CD27+ and
CD8+CD45RO−CD27+ T cells and the CD4:CD8 ratio
(direct correlation with CD4+ T cell counts and inverse
correlation with pVL).
To assign scores, each parameter was divided into
quartiles named from A to D, where A indicated the
most abnormal values, mentioned above that were asso-
ciated with disease progression. Accordingly, for each
parameter, quartile “A” included individuals with the
highest proportion of CD4+HLA-DR+CD38+ and CD8
+HLA-DR+CD38+ T cells, the lowest proportion of CD4
+CD45RO−CD27+ and CD8+CD45RO−CD27+ T cells, as
well as the lowest CD4:CD8 ratio. Conversely, quartile
“D” included subjects with the opposite values for each
parameter, all positively correlated with CD4+ T cell
counts and negatively with pVL. To determine the acti-
vation burden, the number of “A” was calculated for
every donor: for example, an activation burden score of 0
corresponds to having none of the five phenotype parame-
ters at abnormal levels while the score of 3 was defined as
having three or more parameters at abnormal levels.
Statistical analysis
Data analyses were performed using Prism version 5
(GraphPad Inc.), Microsoft Excel (Microsoft) and Stata
version 13 (StataCorp, TX). Groups were compared
using the Mann-Whitney U-test, the Wilcoxon signed
rank test or Fisher’s exact test as appropriate. For
association analyses, the Spearman rank correlation was
determined. P-values ≤ 0.05 were regarded as significant.
Associations of different anti-Tat antibody isotypes with
CD4+ T cell count and viral load were calculated using
uni- and multi-variate Poisson regression with robust
variance estimates. Figure and table legends describe
which test was used in which case. Heatmaps were cre-
ated and hierarchical clustering performed with Qlucore
Omics Explorer 3.2.
Results
Prevalence of anti-Tat humoral responses in chronically
HIV-infected individuals
Previous studies have shown that Mbeya Region is
affected by a multi-clade epidemics characterized by a
high proportion of clade C and AC recombinant forms
of HIV as well as a small fraction of clade D-containing
recombinant forms, while clade B is absent [31–33].
Thus, serum samples were first tested for the presence
of antibodies recognizing clade C Tat. Anti-Tat IgG were
detected in 36 % of HIV-1 infected subjects, anti-Tat IgA
in 14 % and anti-Tat IgM in 49 %. Thirty four % of indi-
viduals did not have serum antibodies recognizing clade
C Tat (Fig. 1a). We then assessed the capacity of the
anti-Tat antibodies in this non-clade B cohort to
recognize clade B Tat. As shown in Fig. 1b, 21 of the 35
(60 %) subjects with detectable anti-clade C Tat IgG also
recognized clade B Tat. Similar proportions were found
for anti-Tat IgA (8 of 13, 62 %), while 37 of the 47
(79 %) subjects with anti-Tat C IgM recognized clade B
Tat, indicating that IgM displayed the highest cross-
reactivity. Notably, some HIV-1 infected individuals rec-
ognized clade B but not clade C Tat (Fig. 1c,d and Add-
itional file 2). Overall, 71 of 96 subjects (74 %) had
detectable antibodies against Tat (clade C and/or B): 44
had IgG, 15 IgA and 49 IgM (Fig. 1e and Additional file
2). Twenty-five out of the 49 anti-Tat IgM responders
did not have anti-Tat IgG, suggesting a lack of isotype
switch despite chronic infection. In contrast, anti-Tat
IgA were mostly found associated with other isotypes, as
only 2 of the 15 anti-Tat IgA responders exclusively
mounted IgA responses (Fig. 1d). These two subjects
might have lost IgG and/or IgM over time, although the
presence of IgA in the absence of other isotypes has
been reported in HIV infection [34, 35].
Together, these analyses demonstrate that a large propor-
tion of the 96 chronically HIV-infected adults had a serum
anti-Tat antibody response dominated by IgG or IgM.
Anti-Tat IgM and IgA are differently associated with
CD4+ T cell count and plasma viremia
To determine the association between anti-Tat antibody
isotypes and CD4+ T cell count, we evaluated the fre-
quencies of subjects with the different anti-Tat isotypes
after stratification according to the immunological HIV
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staging [36]. For each anti-Tat isotype, responders were
considered as those individuals that were positive to at
least one of the two clades (C and/or B). As shown in
Table 2, anti-Tat IgG were present at a similar frequency
in the three groups (>500, 500-200, <200 CD4+ T cells/μl),
while anti-Tat IgA were detected at higher frequency in
subjects with low CD4+ T cell counts. A significantly
higher prevalence of anti-Tat IgM was detected in
individuals with CD4+ T cell counts greater than 500
cells/μl (p-value = 0.008). Anti-Tat antibody-negative
subjects were more likely to have low CD4+ T cell counts,
although this difference was not significant (p-value = 0.27).
Since these data suggest that anti-Tat IgM responses are
associated with a better disease prognosis, and usually IgM
responses tend to disappear over time [37–39], we sought





Fig. 1 Prevalence and cross-clade reactivity of anti-Tat antibodies. CART-naïve, chronically HIV-infected individuals (n = 96) were tested for the presence
of anti-Tat antibodies by ELISA. a Percentage of subjects with anti-clade C Tat IgG, IgA or IgM or anti-clade C Tat negative. b Number of anti-clade C
Tat positive individuals able to recognize clade B Tat. c Number of subjects able to recognize clade B but not clade C Tat. d Heatmap showing, for
single donors, positivity (black) or negativity (grey) toward clade C or clade B Tat for each isotype after unsupervised clustering. e Venn diagram
analyses of the number of subjects recognizing clade B and/or C Tat stratified by the antibody isotype displayed
Table 2 Frequency of anti-Tat antibodies and disease stage
IgG IgA IgM Negative
CD4+ T cells (cells/μl) <200 7/17 (41 %) 4/17 (24 %) 5/17 (29 %) 7/17 (41 %)
200–500 23/48 (48 %) 10/48 (21 %) 22/48 (46 %) 12/48 (25 %)
>500 14/30 (47 %) 1/30 (3 %) 22/30 (73 %) 6/30 (20 %)
p-valuea 0.92 0.05 0.008 0.27
aFrequency of the different anti-Tat antibody isotypes was calculated in every stratum and compared using Freeman-Halton extension of the Fisher’s exact
probability test for a two-rows by three-columns contingency table
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association with high CD4+ T cell counts was dependent on
the duration of HIV infection. Thus, subjects were stratified
according to the duration of infection: less (n = 20) or more
(n = 69) than 3 years. For 7 subjects the duration of infec-
tion could not be established and were therefore excluded
from this analysis.
As shown in Table 3, the proportion of anti-Tat IgG
responders was comparable irrespective of the infection
duration, while IgA were rarely detected in individuals
infected for less than 3 years. Interestingly, IgM were
detected in 75 % of individuals infected for less than
3 years and still maintained in 45 % of subjects
infected for more than 3 years. Multivariate analysis
revealed that the duration of infection did not affect
the association between the presence of anti-Tat IgM,
high CD4+ T cell counts and low viral load and
between the presence of anti-Tat IgA, CD4+ T cell
loss and high viral load (Table 4).
To better understand the association of the different
anti-Tat isotypes with CD4+ T cell numbers, subjects
were stratified into 5 different groups: those displaying
only IgM, only IgG, both IgG and IgM, IgA (irrespective
of the presence of other isotypes, due to the low number
of samples), and those who were anti-Tat antibody nega-
tive (see Table 5).
As shown in Fig. 2a, subjects with only anti-Tat IgM
displayed significantly higher CD4+ T cell counts (median
486 cells/μl) compared to anti-Tat antibody negative indi-
viduals (median 356 cells/μl, p-value = 0.05). The simul-
taneous presence of anti-Tat IgM and IgG was also
associated with a trend towards higher CD4+ T cell counts
(median 501 cells/μl).
We next explored the association of the different anti-
Tat antibody isotypes with plasma viral load (pVL). IgA
responders had significantly higher levels of plasma
viremia (median Log: 5.4 copies/ml) compared to anti-
Tat antibody negative individuals (median Log: 4.9 cop-
ies/ml, p-value = 0.025, Fig. 2b), while subjects posses-
sing only anti-Tat IgM had the lowest median viral load
(median Log: 4.3 copies/ml). The majority of individuals
with high CD4+ T cell counts (>500 cells/μl) and low
pVL (<104 copies/ml) displayed anti-Tat IgG and/or
IgM, while anti-Tat antibody negative subjects or anti-
Tat IgA responders had lower levels of CD4+ T cells and
higher pVL (Fig. 2c).
These results show that anti-Tat IgM antibodies, alone
or in combination with anti-Tat IgG, although declining
with time, are still detectable after 3 years of HIV infec-
tion in many individuals and are associated with slow-
progression, while serum anti-Tat IgA appears later and
are associated with disease progression.
Association between anti-Tat antibodies and T cell
activation
HIV disease progression is characterized by several T cell
abnormalities such as immune activation and loss of naïve
T cells. Thus, an “activation burden” was defined based on
those parameters that correlated with disease progression:
the percentages of HLA-DR+CD38+ CD4+and CD8+ T
cells, the frequency of CD45RO−CD27+ (naïve-like) CD8+
and CD4+ T cells and the CD4:CD8 ratio (see Additional
file 3 for gating strategy).
As shown in Fig. 3a, subjects with activation burden = 0
(no severe immune abnormalities) were more likely to
have IgM in comparison to subjects with moderate (1-2,
p-value = 0.03) or high (>3, p-value = 0.18) activation bur-
den. Conversely, no differences with respect to the pres-
ence of IgG or IgA were detected among subjects with
different activation burden.
We next studied the association of anti-Tat isotypes
with single T cell abnormalities. The presence of IgM
and/or IgG was neither associated with alteration of
CD4:CD8 ratio (Fig. 3b) nor with differences in the ex-
pression of activation and maturation markers (Fig. 3c-d),
except for IgG responders who showed the lowest per-
centage of CD45RO+CD27+CD4+ T cells (p-value = 0.027
compared to anti-Tat antibody negative subjects). Con-
versely, the presence of anti-Tat IgA was associated with
higher percentages of HLA-DR+ CD38+ CD8+ T cells
when compared to anti-Tat antibody negative individuals
(Fig. 3c, p-value = 0.01).
In summary, these data show that anti-Tat of the IgM
isotype were associated with a low activation burden
while anti-Tat IgA were associated with high CD8+ T
cells activation.
Concurrence of anti-Tat IgG and IgM protects from
disease progression
To determine whether the presence of anti-Tat anti-
bodies could protect against AIDS progression, CD4+ T
Table 3 Frequency of anti-Tat antibodies according to the duration of infection
IgG IgA IgM
Time of infection < 3 years > 3 years < 3 years > 3 years < 3 years > 3 years
Anti-Tat antibodies status + 8/20 (40 %) 32/69 (46 %) 1/20 (5 %) 14/69 (20 %) 15/20 (75 %) 31/69 (45 %)
− 12/20 (60 %) 37/69 (54 %) 19/20 (95 %) 55/69 (80 %) 5/20 (25 %) 38/69 (55 %)
p-valuea 0.80 0.17 0.02
aFrequency of the different anti-Tat antibody isotype was calculated in every stratum and compared using Fisher’s exact probability test
Nicoli et al. BMC Infectious Diseases  (2016) 16:344 Page 5 of 12
cell counts were measured 1 year after the baseline anti
Tat measurements. These data were available for 65 of
the 96 subjects (67.7 %). For these individuals we calcu-
lated the difference in CD4+ T cell counts measured at
baseline and after 1 year follow up, expressed as a per-
centage decrease (or increase) and grouped the subjects
into tertiles based on this measure [40, 41]. Subjects
with the lowest CD4 T cell counts (third tertile) experi-
enced the fastest CD4+ T cell decline (median change:
-25.2 %). Those in the middle tertile showed a moderate
decrease or stable CD4+ T cell count (median change:
-8.8 %), while those with the highest CD4 T cell counts
at baseline (first tertile) generally had an increased CD4+
T cell count (median change: +19.6 %). As shown in
Fig. 4a, subjects with the fastest CD4+ T cell decline
(lowest tertile) were more likely to be anti-Tat antibody
negative (p-value = 0.034 vs middle tertile). Moreover,
individuals with both anti-Tat IgG and IgM were
Table 4 Association of different anti-Tat antibody isotypes with CD4+ T cell count and viral load
Associationa of duration of HIV infection and anti-Tat antibody isotype with CD4+ T cell counts (n = 88)
Univariate Multivariate
Covariate Stratum n Mean CD4+ T cells count (cells/μL) IRR 95 % conf.int. p-value IRR 95 % conf.int. p-value
HIV infection (years) >3 69 403 1 – – 1 – –
≤3 19 501 1.24 (0.98 to 1.58) 0.079 1.10 (0.86 to 1.41) 0.443
IgG neg. 48 431 1 – – 1 – –
pos. 40 415 0.96 (0.76 to 1.22) 0.764 0.97 (0.77 to 1.21) 0.761
IgM neg. 43 353 1 – – 1 – –
pos. 45 491 1.39 (1.10 to 1.76) 0.007 1.34 (1.05 to 1.71) 0.019
IgA neg. 73 448 1 – – 1 – –
pos. 15 306 0.68 (0.51 to 0.91) 0.010 0.73 (0.55 to 0.95) 0.020
Associationa of duration of HIV infection and anti-Tat antibody isotype with Log10 VL (n = 83)
Univariate Multivariate
Covariate Stratum n Mean viral load (Log10 copies/ml) IRR 95 % conf.int. p- value IRR 95 % conf.int. p-value
HIV infection (years) >3 65 4.68 1 – – 1 – –
≤3 18 4.26 0.91 (0.79 to 1.05) 0.203 0.96 (0.83 to 1.10) 0.553
IgG neg. 45 4.47 1 – – 1 – –
pos. 38 4.74 1.06 (0.96 to 1.16) 0.230 1.05 (0.96 to 1.15) 0.284
IgM neg. 40 4.84 1 – – 1 – –
pos. 43 4.36 0.90 (0.82 to 0.99) 0.027 0.92 (0.85 to 0.99) 0.037
IgA neg. 68 4.46 1 – – 1 – –
pos. 15 5.20 1.17 (1.08 to 1.26) <0.001 1.13 (1.06 to 1.21) <0.001
IRR incidence rate ratio
aPoisson regression with robust variance estimates was used to examine the association of Tat antibody isotypes with CD4+ T cell count and viral load. The table
shows that the duration of HIV infection and anti-Tat IgG positivity had no significant influence on both parameters, whereas the presence of anti-Tat IgM and IgA
were significantly associated with CD4+ T cell count and viral load. Anti-Tat IgM positivity was associated with higher CD4+ T cell counts and lower viral loads,
whereas anti-Tat IgA positivity showed the opposite pattern. The fact that multivariate IRRs and p-values for both parameters are fairly similar to the univariate
estimates suggest that these associations are independent of each other
Table 5 Stratification of subjects according to anti-Tat antibody isotypes
Antibody response (n) Age: median (range) Females
Isotype (n) IgG IgG IgA IgA IgM IgM
Tat B Tat C Tat B Tat C Tat B Tat C n (%)
IgG (13) 10 6 0 0 0 0 37 (26–45) 9 (69 %)
IgA (15) 8 9 10 13 4 6 40 (25–55) 6 (40 %)
IgM (21) 0 0 0 0 17 19 34 (20–54) 16 (80 %)
IgM + IgG (22) 12 19 0 0 18 22 36 (20–61) 13 (59 %)
Neg (25) 0 0 0 0 0 0 35 (19–53) 14 (56 %)
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significantly more represented in the middle (p-value =
0.0015 vs lowest tertile) and upper (p-value = 0.02 vs
lowest tertile) tertiles, with only one subject present in
the lowest tertile. Notably, these subjects also experi-
enced a significant decrease of the HLA-DR+CD38+CD8+T
cell percentages during this time interval (Fig. 4b, p-value =
0.029).
Together, these results are consistent with the concur-
rence of anti-Tat IgM and IgG being protective with re-
spect to CD4+ T cell decline and exacerbation of
immune activation.
Discussion
Anti-Tat antibodies have been shown to be associated
with slower progression to AIDS [19, 23, 24, 42], and
vaccination with Tat protected HIV-infected subjects
from CD4+ T cells decline and immune dysfunction
[26, 28, 29]. However little is known about the interplay
of different anti-Tat antibody isotypes in HIV control and
their association with immunological abnormalities, espe-
cially in non-clade B cohorts.
In this cohort of chronically HIV-infected subjects
from South West Tanzania, anti-Tat IgM and IgG
showed a similar prevalence (~50 %), while anti-Tat IgA
were detected in only 15 % of subjects. Data from clade B
cohorts show the frequency of anti-Tat IgG to be ~20 %
[17, 21, 43], although higher frequencies have been re-
ported [23, 44], conceivably depending on the cohort and
the assay used to detect anti Tat antibodies.
Tat is a highly conserved protein, not only between
different isolates of the same clade, but also across
clades, and the highest levels of similarity are found in
domains essential for Tat functions and in those contain-
ing immunodominant epitopes [43, 45]. Consistently
with this and with reports showing that anti-Tat anti-
bodies elicited against Tat expressed by one HIV clade
may recognize Tat from different HIV clades [43, 46–48],
our data demonstrate that a high proportion of individuals
with detectable anti-Tat antibodies were able to recognize
both clade B and C Tat. This was observed particularly for
IgM. However, ELISA tests performed to measure anti-
clade B Tat IgM displayed background levels that were
nearly double of those observed measuring anti-clade C
Tat IgM (Additional file 2C). High noise signals that inter-
fered with the detection of anti-clade B Tat IgM have also
been reported by other groups and explained as a cross-
recognition of some endogenous peptides with sequences
similar to clade B Tat [18, 49]. Thus, we cannot exclude
that, among donors with IgM recognizing anti-clade B
Tat, some may actually have antibodies directed against
Fig. 2 Association of anti-Tat antibody isotypes with CD4+ T cell count and viral load. Subjects were stratified according to the type and number
of the anti-Tat antibody isotypes detected. Subgroups were compared for (a) CD4+ T cell count or (b) Log10 plasma viral load. Lines represent
the median value. Statistical comparisons were made using the Mann-Whitney test. c Subjects were plotted according to both CD4+ T cell count
and Log10 plasma viral load. Empty circles represent subjects with anti-Tat IgG and/or IgM but not IgA, grey squares represent subjects with
anti-Tat IgA, black triangles represent anti-Tat antibody negative subjects
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endogenous epitopes and cross-reacting with Tat. How-
ever, the fact that these subjects are also positive for anti-
clade C Tat IgM, whose background levels are low and
similar to those observed for IgA or IgG detection, would
argue in favour of the response observed being a truly
anti-clade B Tat IgM.
Interestingly, some subjects not recognizing clade C
Tat had antibodies against clade B Tat, a subtype absent
in the Mbeya region [31–33]. These subjects could have
been infected either with a clade D subtype, which
shares a common ancestry with clade B [50, 51], or with
HIV-1 from other clades that share certain epitope-
sequences closely related to the tested B sequence.
Chronically HIV-infected individuals with anti-Tat
IgM had relatively high CD4+ T cell counts and low viral
load. Anti-Tat IgM was still detectable after several years
of infection and the duration of infection did not affect
the association of IgM with slow disease progression.
The persistence of IgM during chronic infection is
intriguing and recently described for other infections
[52, 53]. Moreover, anti-Tat IgM has been observed to
also persist in Tat-vaccinated subjects [27], suggesting
that Tat-specific IgM+ memory B cells are long lived.
IgM are highly efficient in activating the complement
system and in inhibiting virus entry by directly interact-
ing with HIV co-receptors [54]. Although further studies
Fig. 3 Association of anti-Tat antibody isotypes with immunological abnormalities. a Subjects were stratified according to the activation burden.
Subjects in panels (b-d) were stratified according to the type and number of anti-Tat antibody isotypes. b Subgroups were compared for CD4:CD8
ratio. c Subgroups were compared for percentages of CD38+ HLA-DR+ on CD8+ (left panel) and CD4+ T cells (right panel). d Subgroups were compared
for CD8+ (left panel) and CD4+ (right panel) T cell subpopulations. Solid lines in panels (b-c) represent the median value while bars in
panel (d) represent the median values with interquartile range. Statistical comparisons were made using Fisher’s exact probability test (a) and
Mann-Whitney test (b-d)
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are needed to determine the precise role of long-lived
anti-Tat IgM, this isotype has been shown in different
context to be highly cross-reactive, protective and to
sustain IgG responses [52, 55, 56]. Moreover, the cross-
recognition of self peptides by anti-Tat IgM [18, 49] may
constitute a potential mechanism of protection as IgM
autoantibodies have been shown to prevent excessive
inflammation [57]. Consistently, we observed less pro-
nounced T cell abnormalities in subjects with anti-Tat
IgM, who prospectively showed a decrease of HLA-
DR+CD38+ and CD45RO+CD27+ CD4+ T cells (Fig. 4b
and Additional file 4 respectively), a cell subset containing
central and transitional memory cells (important viral res-
ervoirs) and whose increased percentage correlated with
progression to AIDS (data not shown). Together, these
data suggest that the presence of anti-Tat IgM may coun-
teract disease progression and, in accordance with reports
from European and American cohorts [17, 18, 22], this
effect is independent of the HIV clade. In addition, the
titer of anti-Tat IgM inversely correlated with the levels of
CD8+ T cells with an effector memory-like phenotype
(CD45RO+CD27−, Additional file 5), a subpopulation in-
duced by Tat [8, 9].
Individuals positive for anti-Tat IgM and developing
IgG responses were protected from rapid CD4+ T cell
decline. However, anti-Tat IgG prevalence did not differ
between patients stratified according to CD4+ T cell
counts, in contrast to observations made with clade B
HIV infected individuals [17, 18]. This implies that an
association of anti-Tat IgG with progression to AIDS
could depend on: i) the HIV clade and/or ii) the pres-
ence of multiple anti-Tat isotypes. Tat is a largely un-
structured and pleiotropic protein formed by several
domains that have different role with respect to HIV
replication in infected CD4+ T lymphocytes and immu-
nomodulatory effects on uninfected cells [2, 58]. Small
differences at the levels of these domains between clade
B and clade C Tat may alter its transcriptional activity
and/or immunomodulatory properties [46, 59–61].
Thus, IgG-mediated neutralization of Tat in clade B and
C HIV-infected individuals may have different clinical
outcomes. In addition, mutations observed between the
Fig. 4 Association of different anti-Tat antibody isotypes with disease progression. a Subjects were stratified according to the tertiles of CD4+ T
cell decline. Black bars represent subjects with any anti-Tat antibody isotype (top panel) or with anti-Tat IgG and IgM (bottom panel). Statistical
comparisons were made using Fisher’s exact probability test. b Subjects were stratified according to the type and number of anti-Tat antibody
isotypes. Subgroups were compared for absolute differences of CD38+HLA-DR+CD8+ T and CD38+HLA-DR+CD4+ T cell percentages. Absolute
differences were obtained by subtracting baseline values from values collected at 1 year follow up visit. Data are presented as Box-and-Whisker
Plots. Statistical significance of absolute difference was calculated using Wilcoxon signed rank test; p-values < 0.05 indicates that differences are
significantly different from 0
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two Tat variants influence the net charge and the iso-
electric point [62], inducing local structural variations
[60, 61, 63] and thus potentially affecting conformational
epitopes. Indeed, clade B Tat is more immunogenic in
animals, compared to other Tat clades [46], and we
cannot exclude that during natural infection clade C Tat
induces IgG directed towards irrelevant or non-
neutralizing epitopes, despite relatively high levels of
binding antibodies cross-recognizing the whole protein.
Further investigations including a proper mapping of
conformational epitopes and neutralization or functional
assays may help to clarify the potential synergy or inter-
ference between different antibody isotypes.
The role of serum HIV-specific IgA has been debated
before. While some reported that serum IgA may display
neutralizing activity [35], results from the recent RV144
trial demonstrated that serum anti-Env IgA may coun-
teract the activity of protective IgG [64]. HIV-infected
individuals with anti-Tat IgA displayed significantly
higher pVL and activation of CD8+ T cells and lower
CD4+ T cell counts. No evidence of accelerated progres-
sion in these subjects was found, although the follow up
period was limited (1 year). Together with the fact that
anti-Tat IgA were almost absent in patients infected for
less than 3 years, this observation indicates that this iso-
type may not necessarily favor disease progression but
rather represents a marker of late progression.
Conclusions
This study characterizes for the first time different anti-
Tat antibody isotype responses in relation to HIV disease
progression in an African cohort. Although additional
longitudinal studies are needed to determine the stability
and persistence of the different anti-Tat antibody iso-
types and their relationship with HIV disease progres-
sion, our data suggest that anti-Tat antibodies are more
prevalent in this non-clade B HIV -infected cohort as
compared with clade B HIV-infected cohorts.
We observed that serum anti-Tat IgA are associated
with high viral load, low CD4+ T cell counts and high
immune activation. Others have already proposed serum
IgA as marker of antiretroviral therapy failure [65], and
our results suggest its use to monitor late stages of dis-
ease even in untreated subjects.
Anti-Tat IgM was associated with slow disease pro-
gression, and this effect was independent of the duration
of infection. Contrary to observations made with clade B
HIV-infected individuals [20–22], anti-Tat IgG alone did
not confer advantages in terms of better prognosis, but
the concurrent presence of IgG and IgM was associated
with a slower CD4+ T cell decline. The identification of
differences in anti-Tat antibody effector functions and
epitope specificity in subjects infected by different HIV
clades may provide further clues for inducing/boosting
effective anti-Tat responses to control HIV infection.
Our data show that anti-clade C Tat immunity is associ-
ated with slow disease progression but is less protective
than anti-clade B Tat immunity.
Injection of clade B Tat induced protective responses
in HIV-1 clade B infected subjects [26, 27]. In addition,
clade B Tat is highly cross-recognized and induces
cross-reactive antibodies [43, 46–48]. Based on our and
others’ findings, we consider the enhancement of anti-
Tat immunity as a promising immunotherapeutic strat-
egy for HIV-infected individuals. To achieve this goal,
vaccination with cross-reactive proteins from heterol-
ogous clades should be further investigated, such as the
use of clade B Tat in clade C HIV-infected cohorts.
Additional files
Additional file 1: Alignment of used clade B and C Tat sequences.
(DOCX 43 kb)
Additional file 2: magnitude of anti-Tat humoral responses: (A)
Anti-clade B and C Tat IgG, IgA or IgM titers were determined in anti-Tat
positive sera and displayed for every donor. (B) Heatmap showing, for
single donors, positivity (black) or negativity (grey) towards clade C or
clade B Tat for each isotype. (C) Optical density (O.D.) from screening
ELISA tests are shown for each donor after cut-off subtraction. Cut-off values
were included in the following ranges: 0.128 ± 0.029 for anti-clade C Tat IgG;
0.1245 ± 0.042 for anti-clade B Tat IgG; 0.1177 ± 0.022 for anti-clade C Tat
IgA; 0.1387 ± 0.031 for anti-clade C Tat IgA; 0.1963 ± 0.060 for anti-clade C
Tat IgM; 0.370 ± 0.086 for anti-clade B Tat IgM. (JPG 154 kb)
Additional file 3: Frequencies of CD4+ and CD8+ T cells expressing
activation and maturation markers in the peripheral blood: Shown are
representative plots demonstrating the gating strategy for the expression
of activation (CD38 and HLA-DR; left panel) and maturation (CD27 and
CD45RO; right panel) markers on CD4+ (upper panels) and CD8+ (lower
panels) T cells. (JPG 316 kb)
Additional file 4: Prospective analysis of the association of different
anti-Tat antibody isotypes with T cell subpopulations. Subjects were
stratified according the type and number of anti-Tat antibody isotypes. Bars
show the proportion of the different subsets in the CD8+ and CD4+ T cell
compartments, based on the median value of each subset measured at
baseline and after 1 year. For each subset, differences from baseline were
calculated using Wilcoxon signed rank test. + and - indicate respectively
significant increases and decreases with p-values < 0.05. (JPG 231 kb)
Additional file 5: Correlation between anti-clade B and C Tat IgM titers
and % of Effector Memory CD8+ T cells: IgM titers from anti-clade B and
C Tat IgM responders (upper and lower panel, respectively) were plotted
against percentage of effector CD45RO+CD27− CD8+ T cells. Correlation
was assessed by Spearman r. (JPG 182 kb)
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